CAH: Specialty and generics growth, strategic M&A, and disciplined investment drive strong outlook
Strong FY 2026 results were driven by specialty and generics, with FY 2027 guidance above long-term targets. Growth is supported by acquisitions, robust specialty and nuclear businesses, and disciplined capital allocation, while AI and cost optimization remain key priorities.Based on Cardinal Healt…
Strong FY 2026 results were driven by specialty and generics, with FY 2027 guidance above long-term targets. Based on Cardinal Healt…